Oxford Biomedica Solutions
Zaid Junaid is an experienced process engineer and scientist with a strong background in downstream process development, purification processes, and project management. Currently serving as an Associate Principal Process Engineer at Landmark Bio since July 2024, Zaid previously held significant positions including Lead Senior Scientist in Downstream Process Development at Candel Therapeutics, where responsibilities included overseeing the purification process development department. At Oxford Biomedica Solutions, Zaid led purification development projects, achieving timely pipeline deliverables and developing a novel chromatography unit operation. Earlier roles at Homology Medicines and Regeneron Pharmaceuticals involved designing scientific experiments and leading cross-functional teams in process validation and technology transfers, as well as work as a Process Engineering Intern at GLOBALFOUNDRIES. Zaid holds a Bachelor's degree in Chemical Engineering from Rensselaer Polytechnic Institute.
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.